ADAG
Adagene Inc.
Price Chart
Latest Quote
$3.32
-0.26 (-7.26%)
Current Price
| Previous Close | $3.58 |
| Open | $3.56 |
| Day High | $3.56 |
| Day Low | $3.16 |
| Volume | 294,481 |
Stock Information
| Shares Outstanding | 66.07M |
| Total Debt | $6.26M |
| Cash Equivalents | $75.84M |
| Revenue | $7.67M |
| Net Income | $-17.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $219.36M |
| EPS (TTM) | $-0.37 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $143.71M |
| Sales | $7.67M |
| Income | $-17.61M |
| Book/sh | $0.75 |
| Cash/sh | $1.15 |
| Employees | 128 |
Financial Ratios
| Quick Ratio | 3.01 |
| Current Ratio | 3.07 |
| Debt/Eq | 12.07 |
Returns & Margins
| ROA | -16.00% |
| ROE | -34.39% |
| Gross Margin | 100.00% |
| Operating Margin | -74.96% |
| Profit Margin | -229.56% |
Ownership
| Insider Ownership | 21.16% |
| Institutional Ownership | 20.09% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.38 |
| P/S | 28.60 |
| P/B | 4.45 |
Analyst Data
| Recommendation | none |
| Target Price | $9.40 |
Technical Indicators
| SMA20 | $3.65 |
| SMA50 | $3.77 |
| SMA200 | $2.65 |
| RSI | 45.45 |
| ATR | 0.3773 |
| Shares Float | 41.42M |
| Short Float | 1.45% |
| Short Ratio | 5.11 |
| Volatility | 0.59 |
| Rel Volume | 1.97 |
Performance History
| Week | -16.37% |
| Month | -8.03% |
| Quarter | +16.90% |
| 6 Months | +61.17% |
| YTD | +80.43% |
| Year | +74.74% |
| 3 Years | +151.52% |
| 5 Years | -76.59% |
| 10 Years | -88.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $3.32 | 294,481 |
| 2026-06-04 | $3.58 | 254,200 |
| 2026-06-03 | $3.46 | 47,700 |
| 2026-06-02 | $3.39 | 175,200 |
| 2026-06-01 | $3.78 | 42,700 |
| 2026-05-29 | $3.97 | 553,200 |
| 2026-05-28 | $3.94 | 233,800 |
| 2026-05-27 | $4.00 | 362,300 |
| 2026-05-26 | $3.72 | 325,800 |
| 2026-05-22 | $3.75 | 69,400 |
| 2026-05-21 | $3.79 | 147,300 |
| 2026-05-20 | $3.45 | 44,600 |
| 2026-05-19 | $3.40 | 32,900 |
| 2026-05-18 | $3.39 | 131,900 |
| 2026-05-15 | $3.50 | 23,500 |
| 2026-05-14 | $3.66 | 2,100 |
| 2026-05-13 | $3.70 | 29,300 |
| 2026-05-12 | $3.66 | 30,900 |
| 2026-05-11 | $3.79 | 80,600 |
| 2026-05-08 | $3.69 | 103,500 |
| 2026-05-07 | $3.58 | 68,200 |
| 2026-05-06 | $3.61 | 128,800 |
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
đ° Latest News
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-06-05T16:00:04Z
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Zacks âĸ 2026-06-02T13:40:03Z
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
MarketBeat âĸ 2026-05-19T21:07:54Z
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Insider Monkey âĸ 2026-04-20T14:15:33Z
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-04-05T05:09:59Z
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon
MarketBeat âĸ 2026-03-10T00:48:40Z
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk
MarketBeat âĸ 2026-02-25T22:25:39Z
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
Zacks âĸ 2026-02-16T12:48:00Z
Penny Stocks To Watch In January 2026
Simply Wall St. âĸ 2026-01-19T12:05:09Z
3 Promising Penny Stocks With Market Caps Over $30M
Simply Wall St. âĸ 2025-12-19T18:05:17Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $7,670,902 | $103,204 | $18,111,491 | $9,292,724 |
| Operating Revenue | $7,670,902 | $103,204 | $18,111,491 | $9,292,724 |
| Expenses | ||||
| Interest Expense | $463,132 | $851,874 | $1,107,820 | $693,323 |
| Total Expenses | $29,109,197 | $36,054,747 | $41,831,357 | $93,213,407 |
| Other Income Expense | $1,690,164 | $-439,592 | $3,289,639 | $4,723,713 |
| Other Non Operating Income Expenses | $323,988 | $466,620 | $1,843,437 | $2,168,388 |
| Net Non Operating Interest Income Expense | $1,840,858 | $2,949,471 | $3,175,265 | $-315,822 |
| Interest Expense Non Operating | $463,132 | $851,874 | $1,107,820 | $693,323 |
| Operating Expense | $29,109,197 | $36,054,747 | $41,831,357 | $93,213,407 |
| General And Administrative Expense | $7,075,624 | $7,273,335 | $8,672,843 | $11,873,867 |
| Other Operating Expenses | - | - | $-3,480,632 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Net Interest Income | $1,840,858 | $2,949,471 | $3,175,265 | $-315,822 |
| Interest Income | $2,303,990 | $3,801,345 | $4,283,085 | $377,501 |
| Normalized Income | $-18,952,865 | $-32,518,375 | $-20,031,022 | $-81,888,341 |
| Net Income From Continuing And Discontinued Operation | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Total Operating Income As Reported | $-21,438,295 | $-35,951,543 | $-23,719,866 | $-83,920,683 |
| Net Income Common Stockholders | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Net Income | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Net Income Including Noncontrolling Interests | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Net Income Continuous Operations | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Pretax Income | $-17,907,273 | $-33,441,664 | $-17,254,962 | $-79,512,792 |
| Interest Income Non Operating | $2,303,990 | $3,801,345 | $4,283,085 | $377,501 |
| Operating Income | $-21,438,295 | $-35,951,543 | $-23,719,866 | $-83,920,683 |
| Per Share | ||||
| Diluted EPS | - | $-0.74 | $-0.44 | $-1.85 |
| Basic EPS | - | $-0.74 | $-0.44 | $-1.85 |
| Other | ||||
| Tax Effect Of Unusual Items | $22,724 | $-476 | $361,550 | $638,831 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,220,526 | $-30,744,717 | $-16,384,886 | $-79,925,264 |
| Total Unusual Items | $1,366,176 | $-906,212 | $1,446,202 | $2,555,325 |
| Total Unusual Items Excluding Goodwill | $1,366,176 | $-906,212 | $1,446,202 | $2,555,325 |
| Reconciled Depreciation | $589,791 | $938,861 | $1,208,458 | $1,449,530 |
| EBITDA (Bullshit earnings) | $-16,854,350 | $-31,650,929 | $-14,938,684 | $-77,369,939 |
| EBIT | $-17,444,141 | $-32,589,790 | $-16,147,142 | $-78,819,469 |
| Diluted NI Availto Com Stockholders | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Tax Provision | $-297,860 | $-17,553 | $1,691,408 | $459,055 |
| Gain On Sale Of Security | $1,366,176 | $-906,212 | $1,446,202 | $2,555,325 |
| Research And Development | $22,033,573 | $28,781,412 | $36,639,146 | $81,339,540 |
| Selling General And Administration | $7,075,624 | $7,273,335 | $8,672,843 | $11,873,867 |
| Other Gand A | $7,075,624 | $7,273,335 | $8,672,843 | $11,873,867 |
| Diluted Average Shares | - | $45,030,322 | $43,790,024 | $43,308,067 |
| Basic Average Shares | - | $45,030,322 | $43,790,024 | $43,308,067 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $35,349,547 | $50,523,844 | $70,559,497 | $83,090,350 |
| Total Assets | $78,263,297 | $89,268,425 | $115,728,838 | $152,399,845 |
| Total Non Current Assets | $888,132 | $1,490,420 | $2,285,109 | $3,084,412 |
| Other Non Current Assets | $25,223 | $81,386 | $84,885 | $109,572 |
| Current Assets | $77,375,165 | $87,778,005 | $113,443,729 | $149,315,433 |
| Other Current Assets | $1,202,755 | $527,706 | $905,425 | $804,992 |
| Prepaid Assets | $1,631,279 | $2,047,488 | $2,382,020 | $4,132,331 |
| Receivables | $17,349 | $8,309 | $222,027 | $619,432 |
| Cash Cash Equivalents And Short Term Investments | $74,523,782 | $85,194,502 | $109,934,257 | $143,758,678 |
| Cash And Cash Equivalents | $74,523,782 | $85,194,502 | $109,934,257 | $143,758,678 |
| Accounts Receivable | - | - | - | $0 |
| Allowance For Doubtful Accounts Receivable | - | - | - | $0 |
| Gross Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $6,263,222 | $18,493,539 | $22,306,871 | $27,971,231 |
| Long Term Debt And Capital Lease Obligation | $1,191,654 | $559,643 | $13,713,694 | $14,200,375 |
| Long Term Debt | $1,138,174 | $417,339 | $13,540,034 | $14,146,541 |
| Current Debt And Capital Lease Obligation | $5,071,568 | $17,933,896 | $8,593,177 | $13,770,856 |
| Current Debt | $4,979,513 | $17,792,555 | $8,397,222 | $13,618,873 |
| Other Current Borrowings | $711,359 | $12,923,599 | $4,161,549 | $2,850,128 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $42,913,750 | $38,744,581 | $45,169,341 | $69,309,495 |
| Total Non Current Liabilities Net Minority Interest | $17,741,654 | $559,643 | $13,713,694 | $14,229,093 |
| Current Liabilities | $25,172,096 | $38,184,938 | $31,455,647 | $55,080,402 |
| Other Current Liabilities | $232,242 | $56,265 | $119,749 | $111,915 |
| Current Deferred Liabilities | $3,462,683 | $0 | $0 | $15,107,276 |
| Payables And Accrued Expenses | $16,405,603 | $20,194,777 | $22,742,721 | $26,090,355 |
| Payables | $14,230,214 | $17,915,708 | $20,371,221 | $23,338,500 |
| Total Tax Payable | $998,507 | $485,969 | $563,143 | $349,039 |
| Income Tax Payable | $410,198 | $5,265 | $52,884 | $0 |
| Accounts Payable | $2,884,507 | $4,241,773 | $3,093,752 | $3,666,124 |
| Other Non Current Liabilities | - | - | - | $28,718 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Non Current Deferred Taxes Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $35,349,547 | $50,523,844 | $70,559,497 | $83,090,350 |
| Total Equity Gross Minority Interest | $35,349,547 | $50,523,844 | $70,559,497 | $83,090,350 |
| Stockholders Equity | $35,349,547 | $50,523,844 | $70,559,497 | $83,090,350 |
| Gains Losses Not Affecting Retained Earnings | $-1,914,831 | $-526,903 | $-1,800,088 | $-849,305 |
| Other Equity Adjustments | $-1,914,831 | $-526,903 | $-1,800,088 | $-849,305 |
| Retained Earnings | $-328,785,000 | $-311,175,587 | $-277,751,476 | $-258,805,106 |
| Preferred Securities Outside Stock Equity | $16,550,000 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $59,231,993 | $58,886,944 | $55,145,839 | $54,065,709 |
| Share Issued | $59,231,993 | $58,886,944 | $55,145,840 | $54,065,710 |
| Tangible Book Value | $35,349,547 | $50,523,844 | $70,559,497 | $83,090,350 |
| Invested Capital | $41,467,234 | $68,733,738 | $92,496,753 | $110,855,764 |
| Working Capital | $52,203,069 | $49,593,067 | $81,988,082 | $94,235,031 |
| Capital Lease Obligations | $145,535 | $283,645 | $369,615 | $205,817 |
| Total Capitalization | $36,487,721 | $50,941,183 | $84,099,531 | $97,236,891 |
| Additional Paid In Capital | $366,043,455 | $362,220,445 | $350,105,518 | $342,739,268 |
| Capital Stock | $5,923 | $5,889 | $5,547 | $5,497 |
| Common Stock | $5,923 | $5,889 | $5,547 | $5,497 |
| Long Term Capital Lease Obligation | $53,480 | $142,304 | $173,660 | $53,834 |
| Current Deferred Revenue | $3,462,683 | $0 | $0 | $15,107,276 |
| Current Capital Lease Obligation | $92,055 | $141,341 | $195,955 | $151,983 |
| Line Of Credit | $4,268,154 | $4,868,956 | $4,235,673 | $10,768,745 |
| Current Accrued Expenses | $2,175,389 | $2,279,069 | $2,371,500 | $2,751,855 |
| Dueto Related Parties Current | $10,347,200 | $13,187,966 | $16,714,326 | $19,323,337 |
| Net PPE | $862,909 | $1,409,034 | $2,200,224 | $2,974,840 |
| Accumulated Depreciation | $-7,846,049 | $-7,300,848 | $-6,708,077 | $-5,909,305 |
| Gross PPE | $8,708,958 | $8,709,882 | $8,908,301 | $8,884,145 |
| Leases | $1,054,204 | $1,030,798 | $1,037,675 | $1,055,271 |
| Other Properties | $1,818,366 | $1,793,132 | $1,818,352 | $1,863,963 |
| Machinery Furniture Equipment | $5,690,853 | $5,602,307 | $5,687,171 | $5,773,034 |
| Buildings And Improvements | $145,535 | $283,645 | $365,103 | $191,877 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $17,349 | $8,309 | $222,027 | $619,432 |
| Treasury Shares Number | - | $0 | $1 | $1 |
| Treasury Stock | - | $0 | $4 | $4 |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,674,503 | $-29,734,565 | $-28,539,851 | $-49,302,625 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,657,450 | $-29,700,985 | $-28,454,839 | $-48,611,687 |
| Cash Flow From Continuing Operating Activities | $-15,657,450 | $-29,700,985 | $-28,454,839 | $-48,611,687 |
| Operating Gains Losses | $-1,364,707 | $908,685 | $-1,436,837 | $-2,548,514 |
| Investing Activities | ||||
| Capital Expenditure | $-17,053 | $-33,580 | $-85,012 | $-690,938 |
| Investing Cash Flow | $476,803 | $1,110,127 | $-77,356 | $-686,046 |
| Cash Flow From Continuing Investing Activities | $476,803 | $1,110,127 | $-77,356 | $-686,046 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $16,550,000 | $7,331,019 | $0 | $0 |
| Financing Cash Flow | $4,445,374 | $3,769,220 | $-5,366,946 | $17,822,973 |
| Cash Flow From Continuing Financing Activities | $4,445,374 | $3,769,220 | $-5,366,946 | $17,822,973 |
| Net Preferred Stock Issuance | $16,550,000 | $0 | $0 | - |
| Preferred Stock Issuance | $16,550,000 | $0 | $0 | - |
| Net Common Stock Issuance | $0 | $7,331,019 | $0 | $-3,976,681 |
| Common Stock Issuance | $0 | $7,331,019 | $0 | $0 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-3,976,681 |
| Net Other Financing Charges | - | $-315,557 | - | - |
| Other | ||||
| Repayment Of Debt | $-17,878,393 | $-8,342,510 | $-13,506,221 | $-4,353,588 |
| Issuance Of Debt | $5,635,488 | $4,918,014 | $8,133,775 | $25,830,030 |
| Interest Paid Supplemental Data | $402,956 | $778,513 | $1,047,717 | $603,680 |
| Income Tax Paid Supplemental Data | $1,602 | $33,947 | $1,376,856 | $2,433,241 |
| End Cash Position | $74,523,782 | $85,194,502 | $109,934,257 | $143,758,678 |
| Beginning Cash Position | $85,194,502 | $109,934,257 | $143,758,678 | $174,391,243 |
| Effect Of Exchange Rate Changes | $64,553 | $81,883 | $74,720 | $842,195 |
| Changes In Cash | $-10,735,273 | $-24,821,638 | $-33,899,141 | $-31,474,760 |
| Proceeds From Stock Option Exercised | $138,279 | $178,254 | $5,500 | $323,212 |
| Net Issuance Payments Of Debt | $-12,242,905 | $-3,424,496 | $-5,372,446 | $21,476,442 |
| Net Long Term Debt Issuance | $-12,242,905 | $-3,424,496 | $-5,372,446 | $21,476,442 |
| Long Term Debt Payments | $-17,878,393 | $-8,342,510 | $-13,506,221 | $-4,353,588 |
| Long Term Debt Issuance | $5,635,488 | $4,918,014 | $8,133,775 | $25,830,030 |
| Net Investment Purchase And Sale | $492,456 | $1,143,538 | $0 | $0 |
| Sale Of Investment | $80,492,456 | $129,643,538 | $47,000,000 | $0 |
| Purchase Of Investment | $-80,000,000 | $-128,500,000 | $-47,000,000 | $0 |
| Net PPE Purchase And Sale | $-15,653 | $-33,411 | $-77,356 | $-686,046 |
| Sale Of PPE | $1,400 | $169 | $7,656 | $4,892 |
| Purchase Of PPE | $-17,053 | $-33,580 | $-85,012 | $-690,938 |
| Change In Working Capital | $-775,300 | $-1,890,455 | $-16,551,790 | $21,938,862 |
| Change In Other Working Capital | $3,462,683 | - | $-15,107,276 | $9,563,113 |
| Change In Other Current Liabilities | $-150,959 | $-220,460 | $-265,784 | $-310,197 |
| Change In Other Current Assets | $56,163 | $3,499 | $24,687 | $-40,297 |
| Change In Payables And Accrued Expense | $-3,863,324 | $-2,611,447 | $-3,250,700 | $6,720,407 |
| Change In Accrued Expense | $-70,225 | $-185,489 | $-122,201 | $-823,928 |
| Change In Payable | $-3,793,099 | $-2,425,958 | $-3,128,499 | $7,544,335 |
| Change In Account Payable | $-1,357,266 | $1,148,021 | $-572,372 | $344,509 |
| Change In Tax Payable | $404,933 | $-47,619 | $52,884 | $-1,657,450 |
| Change In Income Tax Payable | $404,933 | $-47,619 | $52,884 | $-1,657,450 |
| Change In Prepaid Assets | $-270,823 | $724,235 | $1,649,878 | $-881,402 |
| Change In Receivables | $-9,040 | $213,718 | $397,405 | $6,887,238 |
| Other Non Cash Items | $-239,369 | $-1,143,538 | - | - |
| Stock Based Compensation | $3,741,548 | $4,909,573 | $7,271,700 | $10,520,282 |
| Depreciation Amortization Depletion | $589,791 | $938,861 | $1,208,458 | $1,449,530 |
| Depreciation And Amortization | $589,791 | $938,861 | $1,208,458 | $1,449,530 |
| Depreciation | $589,791 | $938,861 | $1,208,458 | $1,449,530 |
| Gain Loss On Investment Securities | $-47,941 | - | - | - |
| Net Foreign Currency Exchange Gain Loss | $-1,318,235 | $906,212 | $-1,446,202 | $-2,555,325 |
| Gain Loss On Sale Of PPE | $1,469 | $2,473 | $9,365 | $6,811 |
| Net Income From Continuing Operations | $-17,609,413 | $-33,424,111 | $-18,946,370 | $-79,971,847 |
| Common Stock Payments | - | $0 | $0 | $-3,976,681 |
| Changes In Account Receivables | - | $0 | $0 | $3,000,000 |
Fetched: 2026-06-02